 Steven Bines
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 60 | 1.470 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2017 | 20 | 0.640 |
Why?
| | Aptitude Tests | 1 | 2013 | 2 | 0.630 |
Why?
| | General Surgery | 2 | 2013 | 55 | 0.620 |
Why?
| | Genetic Therapy | 2 | 2013 | 88 | 0.600 |
Why?
| | Ileal Neoplasms | 1 | 2011 | 2 | 0.550 |
Why?
| | Skin Neoplasms | 2 | 2013 | 138 | 0.520 |
Why?
| | Clinical Competence | 1 | 2013 | 244 | 0.510 |
Why?
| | Herpesvirus 1, Human | 1 | 2010 | 3 | 0.500 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 31 | 0.490 |
Why?
| | Genetic Vectors | 1 | 2010 | 65 | 0.490 |
Why?
| | Laparoscopy | 1 | 2011 | 169 | 0.470 |
Why?
| | Rosaniline Dyes | 1 | 2008 | 3 | 0.450 |
Why?
| | Radioisotopes | 1 | 2008 | 15 | 0.450 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 96 | 0.430 |
Why?
| | Neoplasm Staging | 2 | 2017 | 465 | 0.430 |
Why?
| | Breast Neoplasms | 1 | 2008 | 399 | 0.320 |
Why?
| | Immunotherapy | 2 | 2013 | 63 | 0.300 |
Why?
| | Cancer Vaccines | 2 | 2012 | 19 | 0.270 |
Why?
| | Carcinoma, Renal Cell | 2 | 2012 | 75 | 0.250 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 20 | 0.200 |
Why?
| | Watchful Waiting | 1 | 2017 | 8 | 0.200 |
Why?
| | Lymph Node Excision | 1 | 2017 | 37 | 0.200 |
Why?
| | Humans | 13 | 2017 | 26074 | 0.190 |
Why?
| | Clinical Clerkship | 2 | 2013 | 27 | 0.190 |
Why?
| | Analgesics, Opioid | 1 | 2017 | 118 | 0.190 |
Why?
| | Pain Management | 1 | 2017 | 112 | 0.180 |
Why?
| | Retrospective Studies | 3 | 2017 | 2661 | 0.180 |
Why?
| | Lymph Nodes | 2 | 2017 | 79 | 0.180 |
Why?
| | Chronic Disease | 1 | 2017 | 471 | 0.180 |
Why?
| | Gastrostomy | 1 | 2015 | 10 | 0.170 |
Why?
| | Gastroscopy | 1 | 2015 | 9 | 0.170 |
Why?
| | Mental Disorders | 1 | 2017 | 185 | 0.170 |
Why?
| | Patient Safety | 1 | 2015 | 44 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2015 | 72 | 0.160 |
Why?
| | Animals, Laboratory | 1 | 2013 | 3 | 0.160 |
Why?
| | Adult | 5 | 2017 | 8550 | 0.160 |
Why?
| | Hypopigmentation | 1 | 2013 | 1 | 0.150 |
Why?
| | Vitiligo | 1 | 2013 | 2 | 0.150 |
Why?
| | Students, Medical | 1 | 2013 | 40 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 130 | 0.150 |
Why?
| | Mutant Proteins | 1 | 2013 | 9 | 0.150 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2013 | 8 | 0.150 |
Why?
| | Education, Medical | 1 | 2013 | 37 | 0.150 |
Why?
| | Autoimmunity | 1 | 2013 | 23 | 0.150 |
Why?
| | Animals | 6 | 2013 | 4855 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 37 | 0.150 |
Why?
| | Immunotherapy, Active | 1 | 2012 | 4 | 0.140 |
Why?
| | Middle Aged | 5 | 2017 | 9801 | 0.140 |
Why?
| | Laparoscopes | 1 | 2011 | 3 | 0.140 |
Why?
| | Biopsy, Needle | 1 | 2011 | 114 | 0.130 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 104 | 0.130 |
Why?
| | Defective Viruses | 1 | 2010 | 1 | 0.130 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2010 | 2 | 0.130 |
Why?
| | Injections, Intralesional | 1 | 2010 | 29 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2010 | 59 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 292 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2011 | 466 | 0.120 |
Why?
| | Virus Replication | 1 | 2010 | 88 | 0.120 |
Why?
| | Prospective Studies | 2 | 2013 | 1544 | 0.110 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 131 | 0.110 |
Why?
| | Coloring Agents | 1 | 2008 | 16 | 0.110 |
Why?
| | Mice | 2 | 2013 | 1655 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 104 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2015 | 3258 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2008 | 18 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2010 | 221 | 0.110 |
Why?
| | Research Design | 1 | 2010 | 185 | 0.110 |
Why?
| | Patient Selection | 1 | 2010 | 232 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 176 | 0.110 |
Why?
| | Linear Models | 1 | 2008 | 256 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2008 | 364 | 0.100 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2011 | 260 | 0.100 |
Why?
| | Male | 6 | 2017 | 15162 | 0.100 |
Why?
| | Aged | 4 | 2017 | 8625 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 574 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 807 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2011 | 1798 | 0.090 |
Why?
| | Risk Assessment | 1 | 2008 | 697 | 0.090 |
Why?
| | Female | 5 | 2017 | 15514 | 0.080 |
Why?
| | Cohort Studies | 1 | 2008 | 1575 | 0.080 |
Why?
| | Young Adult | 2 | 2017 | 1849 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 365 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2017 | 953 | 0.050 |
Why?
| | Pain Clinics | 1 | 2017 | 6 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 6 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 96 | 0.050 |
Why?
| | Lymphedema | 1 | 2017 | 21 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2017 | 213 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2017 | 136 | 0.050 |
Why?
| | Palliative Care | 1 | 2017 | 104 | 0.050 |
Why?
| | Survival Analysis | 1 | 2017 | 362 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2017 | 4397 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 507 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 321 | 0.050 |
Why?
| | Ultrasonography | 1 | 2017 | 181 | 0.050 |
Why?
| | Prognosis | 1 | 2017 | 864 | 0.040 |
Why?
| | Antigens | 1 | 2013 | 30 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 18 | 0.040 |
Why?
| | Medical Oncology | 1 | 2013 | 36 | 0.040 |
Why?
| | Vaccination | 1 | 2013 | 29 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 132 | 0.040 |
Why?
| | Transfection | 1 | 2013 | 148 | 0.040 |
Why?
| | Forecasting | 1 | 2013 | 121 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2013 | 61 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2013 | 122 | 0.040 |
Why?
| | Skin | 1 | 2013 | 125 | 0.040 |
Why?
| | Anxiety | 1 | 2013 | 131 | 0.040 |
Why?
| | Disease Management | 1 | 2013 | 115 | 0.040 |
Why?
| | Models, Immunological | 1 | 2012 | 8 | 0.030 |
Why?
| | Peptides | 1 | 2013 | 112 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 35 | 0.030 |
Why?
| | Phenotype | 1 | 2013 | 321 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 210 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 212 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2013 | 228 | 0.030 |
Why?
| | Societies, Medical | 1 | 2013 | 180 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 454 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2013 | 253 | 0.030 |
Why?
| | Inflammation | 1 | 2013 | 289 | 0.030 |
Why?
| | Models, Animal | 1 | 2010 | 147 | 0.030 |
Why?
| | Disease Progression | 1 | 2013 | 741 | 0.030 |
Why?
| | United States | 1 | 2013 | 2029 | 0.020 |
Why?
|
|
Bines's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|